BioDesix Inc (BDSX) is a leading, data-driven diagnostic solutions company pioneering advancements in the field of precision medicine. The company applies artificial intelligence (AI) to empower physicians to make better, more personalized treatment decisions for their patients. Founded in 2005, BioDesix is headquartered in Boulder, Colorado, in the United States.
BioDesix is committed to improving patient outcomes by reducing the uncertainty in the decision-making process. The company uses multi-omic technologies and approaches, alongside machine learning and biostatistics, to discover, develop, and commercialize diagnostic tests. Their products range from congestive heart failure prognostic tests to lung cancer diagnostic tests. BioDesix has developed multiple proprietary technologies, including a platform called Diagnostic Cortex™, which combines machine learning algorithms and custom software tools to analyze large data sets from omics measurements.
BioDesix's flagship product, the VeriStrat test, is a serum proteomic diagnostic that helps physicians make informed treatment decisions for patients with non-small cell lung cancer (NSCLC). Another widely known product, Nodify XL2®, aids physicians in evaluating the risk of lung nodules detected via CT scans as being benign or malignant. Similarly, Nodify CDT helps identify patients' likelihood of having lung cancer based on their current nodule size.
BioDesix's versatile and patient-focused approach is exemplified in the fact that its technology platforms can be applied not just in lung cancer diagnostics but in an array of other diseases as well. This ranges from other cancers to cardiovascular diseases, benefiting a broad array of patients and providers.
With a mission to address unmet clinical needs through translational -omic technologies, data science, digital health, and advanced diagnostics, BioDesix has consistently feed the development of novel diagnostic solutions. It collaborates with biotechnology and pharmaceutical companies to solve complex diagnostic problems and enhance treatment options available to patients.
To summarize, BioDesix Inc. is at the forefront of harnessing the power of AI with the objective of bringing precision medicine solutions to clinical practice. The company continues to innovate and expand its product portfolio to meet the ever-evolving needs of the scientific medical community, ultimately aiming to make a positive impact on patient survival and quality of life. Its works and offerings have made it a key player in the battle against lung cancer, other cancers, and conditions, ultimately benefiting the global healthcare landscape.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
BlackRock Inc. has acquired a new position in Biodesix, Inc. (NASDAQ:BDSX) valued at approximately $970,000, representing a 0.42% stake. This investment comes as other hedge funds also initiated positions, increasing institutional ownership to 20.96%. Biodesix reported better-than-expected quarterly revenue and adjusted EPS, and analysts have a "Moderate Buy" consensus with a price target suggesting potential upside.
Biodesix, Inc. announced its participation in three upcoming investor conferences in September 2026. Members of its leadership team will present at Lake Street Capital Markets' 10th Annual BIG10 Conference, H.C. Wainwright's 28th Annual Global Investment Conference, and the 5th Annual Roth Healthcare Opportunities Conference. At the Roth conference, Biodesix CSO Gary Pestano will participate in a panel discussion on MRD monitoring in solid tumors.
Wall Street analysts are predicting a 26.72% upside for Biodesix (BDSX), with a mean price target of $34.00, despite the stock recently gaining 26.6% over four weeks. While analysts' price targets should be viewed with skepticism due to potential biases, the strong agreement in upward earnings estimate revisions and a Zacks Rank #2 (Buy) suggest a potential for near-term stock appreciation. Investors are advised to use price targets as a starting point for further research rather than the sole basis for investment decisions.
Biodesix Inc (BDSX) shares have recently risen by 9.0% to $30.77, reaching a 52-week high, yet GuruFocus' GF Value™ indicates the stock is 44.8% overvalued with a fair value of $21.25. The company's GF Score™ of 51/100 reflects average performance, with strong growth prospects but poor financial strength and profitability. Despite the overvaluation, there's significant insider buying, with a net purchase of $5.6M over the last year, suggesting confidence from those within the company.
Biodesix (BDSX) shares increased by 10.5% due to investor optimism after Canaccord Genuity raised its price target to $27.00 with a "Buy" rating. The company shows strong progress in top-line growth, operational efficiency, and pipeline advancement, with anticipated revenue growth of 30.4% in its upcoming report. The stock currently holds a Zacks Rank #2 (Buy), supported by a positive trend in earnings estimate revisions.
GSA Capital Partners LLP has acquired a new stake of 46,989 shares in Biodesix, Inc. (NASDAQ:BDSX), valued at approximately $1,060,000, as disclosed in its recent SEC filing. Other institutional investors like AIGH Capital Management LLC and XTX Topco Ltd have also adjusted their positions in Biodesix. Analysts have issued a "Moderate Buy" rating for the company with an average price target of $31.33, while company insiders have also been actively purchasing shares.
AIGH Capital Management LLC has acquired a new stake in Biodesix, Inc. (NASDAQ:BDSX), purchasing 678,328 shares valued at approximately $15.3 million, making it their 18th largest holding. Institutional investors now collectively own 20.96% of Biodesix, while analysts maintain a "Moderate Buy" rating with an average price target of $31.33. Despite the company's continued unprofitability, it recently surpassed quarterly revenue and EPS expectations.